Skip to main content
SpringerLink
Log in

Checkpoint-Inhibitoren beim metastasierten Urothelkarzinom

Firstline-Indikation unter Berücksichtigung der PD-L1-Expression

  • Fortbildung
  • Published:
Uro-News Aims and scope

Die moderne Immuntherapie hat auf urologischem Gebiet in kurzer Zeit Zulassungen beim metastasierten Nieren- sowie Urothelkarzinom erhalten. Gerade beim Urothelkarzinom ist diese Entwicklung von hohem Interesse, da zuvor über mehr als 15 Jahre keine wesentlichen Fortschritte bei der systemischen Therapie erreicht worden sind.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. von der Maase H et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23: 4602–8

    Article  CAS  Google Scholar 

  2. Deutsche S3-Leitlinie „Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms“, Stand 1.11.2016, gültig bis 30.9.2021

  3. De Santis M et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012; 30: 191–9

    Article  CAS  Google Scholar 

  4. Balar AV et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017; 389: 67–76

    Article  CAS  Google Scholar 

  5. Vulky J et al. Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). ASCO 2018, J Clin Oncol. 36, 2018 (suppl; Abstr. 4524)

    Article  Google Scholar 

  6. Dako Denmark A/S, PD-L1 IHC 22C3 pharmDx, Interpretation Manual, Urothelial Carcinoma, Version 05.09.2017, www.agilent.com/cs/library/usermanuals/public/29158_pd-l1-ihc-22C3-pharmdx-nsclc-interpretation-manual.pdf (zugegriffen am 14.1.2019)

  7. Ventana PD-L1 (SP142) Assay Interpretation Guide for Urothelial Carcinoma, www.accessdata.fda.gov/cdrh_docs/pdf16/p160002c.pdf (zugegriffen am 14.1.2019)

  8. O’Donnell PH et al. Biomarker findings and mature clinical results from KEYNOTE-052: First-Line Pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). J Clin Oncol 35, 15_suppl; Abstr. 4502

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Urologie, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Deutschland

    Susan Foller

  2. http://www.springermedizin.de

    Marc-Oliver Grimm

Authors
  1. Susan Foller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc-Oliver Grimm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan Foller.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Foller, S., Grimm, MO. Firstline-Indikation unter Berücksichtigung der PD-L1-Expression. Uro-News 23, 26–28 (2019). https://doi.org/10.1007/s00092-019-2148-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00092-019-2148-7

Search

Navigation